Condition: Diabetic Foot Ulcer (DFU) · Sponsor: New Horizon Medical Solutions
The goal of this clinical trial is to evaluate the clinical outcomes of Diabetic Foot Ulcers (DFUs) treated with a weekly application of Xcell Amnio MatrixTM (XAM) as adjunct to standard of care (SOC) compared to SOC alone in male and female over the age of 18 years old. The main question it aims to answer is: What is the proportion of subjects with complete wound closure during the 12 weeks of the treatment phase? Participants: * Will be screened and re-screened after 2 weeks to be assessed whether they meet the eligibility criteria * Eligible subjects will receive study product application, and for 12 weeks will return to the clinic once every 7 days (±3 days) for treatment visits * Subjects who complete the treatment will be followed up after 2 weeks
This description comes directly from the study's public registry record.
Dawn Shepherd · 817-233-1295 · dawn.shepherd@nhmedical.com
Kher Lee Ng · KherLeeN@amarexcro.com
Always discuss trial participation with your own doctor first.
| Limb Preservation Platform, Inc. | Fresno, California, United States | Recruiting |
| North Park Podiatry | San Diego, California, United States | Recruiting |
| Richard C. Galperin | Dallas, Texas, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07116174